Breaking News Instant updates and real-time market news.

SWTX

SpringsWorks Therapeutics

$31.49 /

+0.475 (+1.53%)

, BGNE

BeiGene

$158.03 /

-0.42 (-0.27%)

08:00
02/27/20
02/27
08:00
02/27/20
08:00

MapKure, SpringsWorks, BeiGene initiate Phase 1 trial of BGB-3245

MapKure, together with BeiGene, Ltd. (BGNE) and SpringWorks Therapeutics, Inc. (SWTX), who are joint owners of MapKure, announced that the first patient has been dosed in Australia in a Phase 1 clinical trial to evaluate BGB-3245, an investigational, next-generation B-RAF inhibitor, in patients with advanced or refractory solid tumors. The companies also announced that the U.S. Food and Drug Administration has allowed the Investigational New Drug application submitted for BGB-3245 to proceed, which will enable study expansion to U.S. sites. The Phase 1 clinical trial is a first-in-human, open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics and antitumor activity of BGB-3245 in adult patients with solid tumors, including those harboring specific B-RAF driver mutations and fusions that are likely to respond to a RAF dimer inhibitor, as well as in certain adult patients who have developed resistance to first-generation B-RAF V600 inhibitors. The trial is designed to define the dose and assess the tolerability of BGB-3245 and will capture early antitumor activity signals to allow for potential cohort expansion. In addition, MapKure has completed the formation of its Scientific Advisory Board, comprised of renowned leaders in MAPK pathway biology and targeted oncology clinical development. The SAB will continue to collaborate with MapKure's joint steering committee, consisting of representatives from BeiGene and SpringWorks, to support the advancement of BGB-3245.

SWTX

SpringsWorks Therapeutics

$31.49 /

+0.475 (+1.53%)

BGNE

BeiGene

$158.03 /

-0.42 (-0.27%)

  • 27

    Feb

  • 02

    Mar

SWTX SpringsWorks Therapeutics
$31.49 /

+0.475 (+1.53%)

01/21/20 H.C. Wainwright
SpringsWorks price target raised to $40 from $34 at H.C. Wainwright
12/04/19
Fly Intel: Top five analyst initiations
12/04/19 H.C. Wainwright
SpringsWorks Therapeutics initiated with a Buy at H.C. Wainwright
10/08/19
Wedbush bullish on SpringsWorks Therapeutics, initiates with an Outperform
BGNE BeiGene
$158.03 /

-0.42 (-0.27%)

02/18/20 Goldman Sachs
BeiGene reinstated with a Buy at Goldman Sachs
01/27/20 Cowen
BeiGene price target lowered to $200 from $216 at Cowen
01/17/20 CLSA
BeiGene upgraded to Buy from Outperform at CLSA
01/17/20
Fly Intel: Top five analyst initiations

TODAY'S FREE FLY STORIES

Hot Stocks
SuperCom ships coronavirus quarantine compliance technology for pilot » 06:54
03/30/20
03/30
06:54
03/30/20
06:54
SPCB

SuperCom

$0.49 /

-0.058 (-10.58%)

SuperCom announced that…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Volvo upgraded to Outperform from Underperform at Exane BNP Paribas » 06:54
03/30/20
03/30
06:54
03/30/20
06:54
VOLVY

Volvo

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Iliad upgraded to Overweight from Equal Weight at Barclays » 06:53
03/30/20
03/30
06:53
03/30/20
06:53
ILIAF

Iliad

$0.00 /

+ (+0.00%)

Barclays analyst Mathieu…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Nexans upgraded to Outperform from Neutral at Exane BNP Paribas » 06:53
03/30/20
03/30
06:53
03/30/20
06:53
NXPRF

Nexans

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Legrand upgraded to Outperform from Neutral at Exane BNP Paribas » 06:52
03/30/20
03/30
06:52
03/30/20
06:52
LGRVF

Legrand

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Eagle Pharmaceuticals: SymBio completes enrollment in TREAKISYM trial » 06:52
03/30/20
03/30
06:52
03/30/20
06:52
EGRX

Eagle Pharmaceuticals

$39.97 /

-2.43 (-5.73%)

Eagle Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Schneider Electric upgraded to Outperform from Neutral at Exane BNP Paribas » 06:51
03/30/20
03/30
06:51
03/30/20
06:51
SBGSY

Schneider Electric

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
BP Midstream price target lowered to $13 from $17 at Mizuho » 06:50
03/30/20
03/30
06:50
03/30/20
06:50
BPMP

BP Midstream

$8.52 /

-0.495 (-5.49%)

Mizuho analyst Gabriel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Downgrade
Medical Properties Trust downgraded to Neutral from Buy at Mizuho » 06:49
03/30/20
03/30
06:49
03/30/20
06:49
MPW

Medical Properties Trust

$17.68 /

+0.13 (+0.74%)

Mizuho analyst Omotayo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Schaeffler AG upgraded to Outperform from Neutral at Exane BNP Paribas » 06:49
03/30/20
03/30
06:49
03/30/20
06:49
SCFLF

Schaeffler AG

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Alphabet upgraded to Outperform from Market Perform at BMO Capital » 06:49
03/30/20
03/30
06:49
03/30/20
06:49
GOOGL

Alphabet Class A

$1,109.46 /

-53.25 (-4.58%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Cresco Labs price target lowered to $10 from $12 at Cantor Fitzgerald » 06:48
03/30/20
03/30
06:48
03/30/20
06:48
CRLBF

Cresco Labs

$0.00 /

+ (+0.00%)

Cantor Fitzgerald analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
New York Mortgage says 'exploring additional financing options' » 06:48
03/30/20
03/30
06:48
03/30/20
06:48
NYMT

New York Mortgage

$1.89 /

+0.075 (+4.13%)

New York Mortgage Trust…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Eli Lilly receives FDA approval for Taltz sBLA » 06:48
03/30/20
03/30
06:48
03/30/20
06:48
LLY

Eli Lilly

$134.03 /

-0.55 (-0.41%)

Eli Lilly announced the…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Valeo upgraded to Neutral from Underperform at Exane BNP Paribas » 06:48
03/30/20
03/30
06:48
03/30/20
06:48
VLEEY

Valeo

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Magellan Midstream price target lowered to $43 from $68 at Mizuho » 06:47
03/30/20
03/30
06:47
03/30/20
06:47
MMP

Magellan Midstream

$33.53 /

-0.92 (-2.67%)

Mizuho analyst Gabriel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Earnings
TCR2 Therapeutics reports Q4 EPS (54c), consensus (67c) » 06:47
03/30/20
03/30
06:47
03/30/20
06:47
TCRR

TCR2 Therapeutics

$6.90 /

-0.22 (-3.09%)

TCR2 ended 2019 with…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Shell Midstream price target lowered to $14 from $19 at Mizuho » 06:46
03/30/20
03/30
06:46
03/30/20
06:46
SHLX

Shell Midstream

$9.57 /

-0.48 (-4.78%)

Mizuho analyst Gabriel…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Epiroc upgraded to Neutral from Underperform at Exane BNP Paribas » 06:46
03/30/20
03/30
06:46
03/30/20
06:46
EPOKY

Epiroc

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Goldman Sachs price target lowered to $245 from $260 at Citi » 06:45
03/30/20
03/30
06:45
03/30/20
06:45
GS

Goldman Sachs

$158.12 /

-7.94 (-4.78%)

Citi analyst Keith…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Criteo upgraded to Outperform from Market Perform at BMO Capital » 06:45
03/30/20
03/30
06:45
03/30/20
06:45
CRTO

Criteo

$7.87 /

+0.62 (+8.55%)

BMO Capital analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Assa Abloy upgraded to Neutral from Underperform at Exane BNP Paribas » 06:44
03/30/20
03/30
06:44
03/30/20
06:44
ASAZY

Assa Abloy

$0.00 /

+ (+0.00%)

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Ready Capital provides company update amid COVID-19 pandemic » 06:43
03/30/20
03/30
06:43
03/30/20
06:43
RC

Ready Capital

$7.21 /

+0.02 (+0.28%)

Ready Capital announced a…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Almirall upgraded to Outperform from Neutral at Exane BNP Paribas » 06:43
03/30/20
03/30
06:43
03/30/20
06:43
LBTSF

Almirall

/

+

Exane BNP Paribas analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Recommendations
Cars.com price target lowered to $8 from $12 at Citi » 06:43
03/30/20
03/30
06:43
03/30/20
06:43
CARS

Cars.com

$3.70 /

-0.58 (-13.55%)

Citi analyst Nicholas…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.